Consumer group finds contaminants in Chinese medicine samples focustaiwan.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from focustaiwan.tw Daily Mail and Mail on Sunday newspapers.
The Asia-Pacific Region: A Hot Spot For Clinical Trials
By Mathini Ilancheran, principal analyst, R&D, Beroe Inc.
Introduction
The Asia-Pacific region has become the hot spot for conducting clinical trials due to the ease of regulatory compliance, the low cost of conducting studies, a growing patient population, and the presence of a few top clinical institutions acting as sites. For example, the regulatory agencies in China are working toward an enhanced clinical trial process by reducing the overall review and approval process.
1
The clinical trial workforce contributes to around 30 to 35% of the overall trial cost. This makes FTE rates for clinical research a key parameter to consider. These rates are generally higher in the developed markets as compared to the Asia-Pacific region, which is why the latter is becoming an important location for conducting clinical trial studies. Also, the cost per patient across all therapeutic areas and phases is much lower in Asian countries
The Asia-Pacific Region: A Hot Spot For Clinical Trials
By Mathini Ilancheran, principal analyst, R&D, Beroe Inc.
Introduction
The Asia-Pacific region has become the hot spot for conducting clinical trials due to the ease of regulatory compliance, the low cost of conducting studies, a growing patient population, and the presence of a few top clinical institutions acting as sites. For example, the regulatory agencies in China are working toward an enhanced clinical trial process by reducing the overall review and approval process.
1
The clinical trial workforce contributes to around 30 to 35% of the overall trial cost. This makes FTE rates for clinical research a key parameter to consider. These rates are generally higher in the developed markets as compared to the Asia-Pacific region, which is why the latter is becoming an important location for conducting clinical trial studies. Also, the cost per patient across all therapeutic areas and phases is much lower in Asian countries
Taiwan recalls Japanese vitamin B supplements due to degradation
02/05/2021 11:25 PM
Photo courtesy of the FDA
Taipei, Feb. 5 (CNA) Some 900,000 Japanese-made vitamin B complex supplements are being recalled because they were found to have lost their potency over time, Taiwan s Food and Drug Administration (FDA) said Friday.
The recall is for the VITRIC Tablets brand dietary supplement produced by Japanese firm Kobayashi Pharmaceutical Co.
The Taipei-based Shiang Chuan Brother Trading Co., which represents the brand in Taiwan, has until March 2 to complete the recall of the tablets (batch numbers: T8DS01, T8DS02, T8DS3 and T8DS04), said Hung Kuo-teng (洪國登), who heads the FDA s Medicinal Products Division.
FDA recalls 9,000 vials of cancer medicine Gemmis
Staff writer, with CNA
The Food and Drug Administration (FDA) yesterday said it has ordered TTY Biopharm Co Ltd (台灣東洋藥品) to recall 9,000 vials of a cancer drug after they were found to have been contaminated by extraneous material.
The drug, Gemmis Injection, is sold in 38ml vials and is usually used in combination with other medicines, such as gemcitabine and paclitaxel, to treat cancer of the lungs, pancreas, bladder or breast in specific cases, the FDA said.
The FDA urged people using Gemmis not to stop using it on their own and to ask their doctor to prescribe alternate medication.